These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38218752)

  • 21. Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy.
    Gros M; Nunes AM; Daoudlarian D; Pini J; Martinuzzi E; Barbosa S; Ramirez M; Puma A; Villa L; Cavalli M; Grecu N; Garcia J; Siciliano G; Solé G; Juntas-Morales R; Jones PL; Jones T; Glaichenhaus N; Sacconi S
    J Neuromuscul Dis; 2022; 9(1):83-93. PubMed ID: 34459413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD).
    Hamel J; Johnson N; Tawil R; Martens WB; Dilek N; McDermott MP; Heatwole C
    Neurology; 2019 Sep; 93(12):e1180-e1192. PubMed ID: 31409737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial.
    Voet NB; Bleijenberg G; Padberg GW; van Engelen BG; Geurts AC
    BMC Neurol; 2010 Jun; 10():56. PubMed ID: 20591139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.
    Katz NK; Hogan J; Delbango R; Cernik C; Tawil R; Statland JM
    Brain; 2021 Dec; 144(11):3451-3460. PubMed ID: 34542603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the influence of smoking and alcohol consumption on clinical severity in patients with facioscapulohumeral muscular dystrophy.
    Vincenten SCC; Mul K; Schreuder THA; Voermans NC; Horlings CGC; van Engelen BGM
    Neuromuscul Disord; 2021 Sep; 31(9):824-828. PubMed ID: 34407911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The facioscapulohumeral muscular dystrophy Rasch-built overall disability scale (FSHD-RODS).
    Mul K; Hamadeh T; Horlings CGC; Tawil R; Statland JM; Sacconi S; Corbett AJ; Voermans NC; Faber CG; van Engelen BGM; Merkies ISJ
    Eur J Neurol; 2021 Jul; 28(7):2339-2348. PubMed ID: 33838063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reliability and validity of the FSHD-composite outcome measure in childhood facioscapulohumeral dystrophy.
    de Valle K; Dobson F; Woodcock I; Carroll K; Ryan MM; Heatwole C; Eichinger K; McGinley JL
    Neuromuscul Disord; 2021 Aug; 31(8):706-715. PubMed ID: 34210539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining the role of sarcomeric proteins in facioscapulohumeral muscular dystrophy: a study protocol.
    Lassche S; Ottenheijm CA; Voermans NC; Westeneng HJ; Janssen BH; van der Maarel SM; Hopman MT; Padberg GW; Stienen GJ; van Engelen BG
    BMC Neurol; 2013 Oct; 13():144. PubMed ID: 24119284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upper limb function and activity in people with facioscapulohumeral muscular dystrophy: a web-based survey.
    Bergsma A; Cup EH; Janssen MM; Geurts AC; de Groot IJ
    Disabil Rehabil; 2017 Feb; 39(3):236-243. PubMed ID: 26942834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of the patient-reported "Facial Function Scale" for facioscapulohumeral muscular dystrophy.
    Mul K; Wijayanto F; Loonen TGJ; Groot P; Vincenten SCC; Knuijt S; Groothuis JT; Maal TJJ; Heskes T; Voermans NC; Engelen BGMV
    Disabil Rehabil; 2023 May; 45(9):1530-1535. PubMed ID: 35575310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. It's not just physical: a qualitative study regarding the illness experiences of people with facioscapulohumeral muscular dystrophy.
    Bakker M; Schipper K; Geurts AC; Abma TA
    Disabil Rehabil; 2017 May; 39(10):978-986. PubMed ID: 27211201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrasound Imaging of Muscle Contraction of the Tibialis Anterior in Patients with Facioscapulohumeral Dystrophy.
    Gijsbertse K; Goselink R; Lassche S; Nillesen M; Sprengers A; Verdonschot N; van Alfen N; de Korte C
    Ultrasound Med Biol; 2017 Nov; 43(11):2537-2545. PubMed ID: 28764967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perturbation of muscle metabolism in patients with muscular dystrophy in early or acute phase of disease: In vitro, high resolution NMR spectroscopy based analysis.
    Srivastava NK; Yadav R; Mukherjee S; Sinha N
    Clin Chim Acta; 2018 Mar; 478():171-181. PubMed ID: 29278724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muscle fibrosis as a prognostic biomarker in facioscapulohumeral muscular dystrophy: a retrospective cohort study.
    Ragozzino E; Bortolani S; Di Pietro L; Papait A; Parolini O; Monforte M; Tasca G; Ricci E
    Acta Neuropathol Commun; 2023 Oct; 11(1):165. PubMed ID: 37849014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herbal medicine significantly improved muscle function in a patient with type 1 facioscapulohumeral muscular dystrophy: A case report.
    Li H; Huang H; Long W; Zuo J; Huang H
    Explore (NY); 2021; 17(3):247-251. PubMed ID: 32505519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical activity practiced at a young age is associated with a less severe subsequent clinical presentation in facioscapulohumeral muscular dystrophy.
    Bettio C; Banchelli F; Salsi V; Vicini R; Crisafulli O; Ruggiero L; Ricci G; Bucci E; Angelini C; Berardinelli A; Bonanno S; D'Angelo MG; Di Muzio A; Filosto M; Frezza E; Maggi L; Mongini T; Pegoraro E; Rodolico C; Scarlato M; Vattemi G; Velardo D; Tomelleri G; D'Amico R; D'Antona G; Tupler R
    BMC Musculoskelet Disord; 2024 Jan; 25(1):35. PubMed ID: 38183077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy.
    Morís G; Wood L; FernáNdez-Torrón R; González Coraspe JA; Turner C; Hilton-Jones D; Norwood F; Willis T; Parton M; Rogers M; Hammans S; Roberts M; Househam E; Williams M; Lochmüller H; Evangelista T
    Muscle Nerve; 2018 Mar; 57(3):380-387. PubMed ID: 29053898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of a model of fatigue in neuromuscular disorders: a longitudinal study.
    Kalkman JS; Schillings ML; Zwarts MJ; van Engelen BG; Bleijenberg G
    J Psychosom Res; 2007 May; 62(5):571-9. PubMed ID: 17467412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The strength and functional performance in patients with facioscapulohumeral muscular dystrophy.
    Lue YJ; Chen SS
    Kaohsiung J Med Sci; 2000 May; 16(5):248-54. PubMed ID: 10969520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A longitudinal study of disease progression in facioscapulohumeral muscular dystrophy (FSHD).
    Varma A; Todinca MS; Eichinger K; Heininger S; Dilek N; Martens W; Tawil R; Statland J; Kissel JT; McDermott MP; Heatwole C
    Muscle Nerve; 2024 Mar; 69(3):362-367. PubMed ID: 38189531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.